Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
Pfizer said it still plans to release phase two trial data on a once-a-day version of its weight loss drug, known as danuglipron, in mid-2024.
Similar Posts
E-commerce stocks rally after Black Friday shoppers spend record online
Shares of e-commerce stocks such as Shopify, Etsy and Wayfair all surged Monday on strong Black Friday online sales and rosy projections for Cyber Monday. Post Views: 113
German business sentiment improves in November – Ifo
Post Content Post Views: 117
Oil little changed as OPEC+ decision awaits, Black Sea storm disrupts supply
Post Content Post Views: 106
First Trust Mortgage Income Fund declares raises dividend by 17.9% to $0.0825
Post Content Post Views: 131
Week after shock Wilders win, Dutch government talks set to begin
Post Content Post Views: 117
‘A lot quieter’ Black Friday brings out discount hunters
Post Content Post Views: 111